Corgentech has reported clinical results from a Phase II trial of 4975, the company's novel, long-acting, non-opioid drug candidate being developed in multiple mid-stage clinical trials for site-specific, moderate to severe pain.
The 41-patient, randomized, double-blind, parallel-group, placebo- controlled European study was designed to measure the effectiveness of 4975 in treating pain induced by surgical repair of an inguinal (groin) hernia as measured one and four weeks after surgery. Patients were given either a single dose of 4975 or placebo, which was instilled (dripped by syringe) into the wound over approximately one minute prior to wound closure. All patients in both the treatment and placebo arms received paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs for one week following surgery. While 4975 was well-tolerated at all time points during the study, there was no significant difference in pain score in the drug versus control arm.